Monday, August 8, 2016

Cleave Biosciences Gets $37M

Burlingame-based Cleave Biosciences, a developer of protein-based technology for treating cancer, has raised $37M in a Series B funding round. The funding came from Celgene, Nextech Invest Ltd. and Arcus Ventures, plus 5AM Ventures, Clarus Ventures, New Enterprise Associates (NEA), Orbimed Advisors, U.S. Venture Partners, Astellas Venture Management and Osage University Partners. Alfred Scheidegger of Nextech Invest, and Carol Gallaghers of NEA have boh joined the companys board of directors. Laura Shawver, Ph.D. is CEO of Cleave Biosciences. More information »